As the calendar turned from April to May, a big change came to the FDA. | Katherine Szarama, Ph.D., will take over as CBER ...
On May 31, 2024, the FDA announced initiation of the Support for Clinical Trials Advancing Rare Disease Therapeutics (“START”) pilot program. The START program, led by the Center for Biologics ...
The FDA and EMA have set out updated regulatory agendas that will shape biologics manufacturing standards in coming years. The FDA’s Center for Biologics Evaluation and Research (CBER) 2026 agenda ...
Cell and gene therapy manufacturers may not like the idea of spending more money on US Food and Drug Administration (FDA) reviewers, but a top official said if a new pilot project goes according to ...
The US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) on Thursday announced the availability of an electronic submission system for companies to submit ...